FROM PUBLIC EVENTS · 2026-11-18

Current stage

  1. Discovery · preclinical
  2. Early clinical · first deals
  3. Late clinical · capacity
  4. Commercial · sales
  1. Global approvals · expansion
  2. M&A · integration
  3. Pipeline reshaping

Early clinical · first deals Has two AI-discovered cancer candidates at the Phase 1 stage and is in licensing talks.

  • Announced first patient dosing in the Korean Phase 1 trial of PHI-501. Source
  • Announced its BIO-Europe 2026 attendance and licensing talks. Source

Roles often seen at this stageClinical & PV · Research & development · BD & licensing

Companies at the same stage and their people flow →

← Company library
Korea / Company briefSources checked 2026-11-18

Pharos iBio

A drug developer that discovers and develops cancer drug candidates with its Chemiverse AI platform.

PHI-101 (rasmotinib)

Phase 1

A candidate for FLT3-mutated acute myeloid leukaemia that completed a global Phase 1 in relapsed or refractory patients, reporting a 50.0% composite complete remission rate and 66.7% objective response rate in evaluable Phase 1b patients.

PHI-501

Phase 1

A solid-tumour candidate that inhibits BRAF and DDR1/2, in a Korean Phase 1 trial for patients with BRAF, KRAS or NRAS mutations at Severance, Samsung Medical Center and Kyungpook National University Chilgok Hospital.

Chemiverse

Technology platform

The company's in-house AI drug discovery platform, used for candidate discovery and indication expansion (DeepRECOM module).

Completion reported

Attended BIO-Europe 2026 for licensing and co-development talks on its cancer candidates.

Completion reported

Began first patient dosing in the Korean Phase 1 trial of PHI-501.

Official role guide

Pharos iBio careers

Current availability unconfirmed

Observed 2026-11-18

Work
Unconfirmed — The official careers page could not be confirmed.
Experience & requirements
Unconfirmed — The official careers page could not be confirmed.

Information from a role guide does not establish a current vacancy.

Sources & coverage 2

A brief based on selected official material, not an exhaustive product or vacancy list.

  1. 파로스아이바이오, 고형암 신약 'PHI-501' 임상 1상 투약 개시 ↗헤럴드경제 · Published 2026-01-29 · Sources checked 2026-11-18 · Original unavailable
  2. 파로스아이바이오, 항암 신약 기술수출 추진‥'바이오유럽 2026' 참가 ↗메디파나뉴스 · Published 2026-11-09 · Sources checked 2026-11-18 · Original unavailable